Financial Data and Key Metrics Changes - Sangamo Therapeutics reduced non-GAAP operating expenses by nearly half year-over-year since 2023 [9] - The company raised over $100 million in funding through non-dilutive license fees, milestone payments, and equity financing in 2024 [9] Business Line Data and Key Metrics Changes - The company advanced its neurology therapies, securing its first-ever neurology IND for idiopathic small fiber neuropathy [7] - The Fabry gene therapy study continues to generate best-in-class data, with pivotal data readout expected in mid-2025 [9][22] Market Data and Key Metrics Changes - Interest in the Fabry program has been strong, with ongoing business development negotiations for a commercial partner [11] - The company is actively engaged in advanced contract negotiations for a third STAC-BBB license agreement [13] Company Strategy and Development Direction - Sangamo's number one priority is addressing financing needs to ensure the company is well-capitalized for future success [11] - The company aims to secure a partnership for the Fabry program by the second quarter of 2025 [12] - The regulatory pathway for accelerated approval in Fabry disease could reduce the time to potential approval by approximately three years [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in transitioning to a clinical-stage neurology company [28] - The company is focused on raising additional capital to support its programs and is in late-stage negotiations for a third STAC-BBB license agreement [30] Other Important Information - The company plans to begin patient enrollment and dosing for ST-503 in mid-2025, with preliminary proof of efficacy data expected in the fourth quarter of 2026 [19] - The FDA has provided a clear regulatory pathway to accelerate approval for ST-920, with full 52-week data expected in the first half of 2025 [25] Q&A Session Summary Question: Is the company still waiting on any data for the Fabry program? - Management confirmed they are in late-phase discussions with several partners and are looking forward to positive data from the ongoing studies [34] Question: Have potential partners seen any data beyond the WORLDSymposium data? - Management indicated that while partners have seen broader data, they have not seen later efficacy data beyond what was presented [45] Question: What is the status of the STAC-BBB deal? - Management hopes to finalize the deal by the end of the quarter and indicated that the partner is a logical blue-chip choice [55] Question: How is the company managing operating expenses going forward? - The company has reduced operating expenses significantly and plans to maintain the same level of expenses as last year while advancing its neurology pipeline [58] Question: What are the patient enrollment criteria for the Nav1.7% study? - Management stated that the criteria will be published on clinical trial registries, emphasizing the importance of a clear result for the one-time treatment [73]

Contango Ore (CTGO) Q4 2024 Earnings Call March 18, 2025 12:51 AM ET Company Participants Romeo Maione - VP Business SolutionsRick Van Nieuwenhuyse - President, CEO & DirectorMichael Clark - CFO Romeo Maione Today, I saw some early rising Australians on the list, so thank you very much for joining us. Appreciate particularly everybody joining us on St. Patrick's Day for a corporate update and Q and A session from Tango Ur related to this morning's press release regarding 2024 earnings. I'm joined today by t ...

Energy Vault (NRGV) Q4 2024 Earnings Call March 18, 2025 12:37 AM ET Company Participants Michael Beer - CFO & Head of Corporate ServicesRobert Piconi - Chairman & CEOChris Ellinghaus - Managing Director Conference Call Participants Thomas Boyes - Analyst Operator Greetings, and welcome to the Energy Vault's Fourth Quarter twenty twenty four Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. It is now my pleasure to int ...

Belite Bio (BLTE) Q4 2024 Earnings Call March 17, 2025 10:58 PM ET Company Participants Julie Fallon - Managing DirectorYu-Hsin Lin - Chairman of the Board of Directors & CEONathan L. Mata - Chief Scientific OfficerHendrik Scholl - CMOHao-Yuan Chuang - CFO & DirectorJennifer Kim - Equity Research DirectorBasma Radwan - Equity Research AssociateYi Chen - Managing Director, Equity Research Conference Call Participants Bruce Jackson - Senior AnalystMichael Okunewitch - Senior Biotechnology Analyst Operator Lad ...

RF Industries (RFIL) Q1 2025 Earnings Call March 17, 2025 10:34 PM ET Company Participants Donni Case - Investor RelationsRobert Dawson - CEORay Bibisi - COO & PresidentPeter Yin - CFOMatthew Maus - Equity Research AssociateSteven Kohl - Partner Operator Please note this conference is being recorded. I will now turn the conference over to your host, Donnie Case, Investor Relations at RF Industries. You may begin. Donni Case Thank you, Paul, and good afternoon, everyone, and welcome to RF Industries' first q ...

Financial Data and Key Metrics Changes - In Q4 2024, revenue grew to $247.3 million, representing a 9.5% increase or 8.5% on a currency-neutral basis [9][18] - For the full year 2024, revenue was $939.3 million, an increase of 2.5% on both reported and currency-neutral basis [10][18] - Adjusted EBITDA for Q4 was $80.6 million, up 11.7% year-over-year, with an adjusted EBITDA margin of 32.6%, up from 31.9% in Q4 2023 [28][29] - Full year adjusted EBITDA was $300 million, with a margin of 32% compared to 32.9% in 2023 [29] Business Line Data and Key Metrics Changes - Annual subscription revenue accounted for 54.9% of total revenue in Q4, growing approximately 11% on both reported and currency-neutral basis [19] - Paid downloads decreased slightly to $93 million, while video attachment rate increased to 16.5% from 14.1% in Q4 2023 [21] - Creative revenue was $142.4 million, down 2.4% year-on-year, primarily due to a shift in download consumption from creative to editorial [22][23] - Editorial revenue increased to $90.1 million, up 19% year-on-year, driven by major events [21] Market Data and Key Metrics Changes - The Americas region saw a revenue increase of 15.9% in Q4 on a currency-neutral basis, while APAC was up 0.4% and EMEA down just under 1% [18] - The corporate segment remains the largest growth opportunity, while Agency is expected to stabilize without significant growth [60] Company Strategy and Development Direction - The merger with Shutterstock is viewed as a transformational opportunity, aimed at creating superior value for customers and shareholders [8] - Continued investment in core assets and partnerships, along with the launch of new AI capabilities, is part of the strategy to enhance customer value [14][15] - The company aims to reduce leverage and increase margins and cash flow through the merger [15][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future despite challenges such as the Los Angeles fires impacting production [15] - The company anticipates revenue for 2025 to be between $918 million and $955 million, reflecting a slight decline to modest growth [40] - Adjusted EBITDA for 2025 is expected to be between $272 million and $290 million, indicating a potential decline year-over-year [41] Other Important Information - Free cash flow for Q4 was $24.6 million, an increase from $18.6 million in Q4 2023, while full year free cash flow was $60.9 million, down from $75.7 million in 2023 [32] - The company completed a refinancing of term loans, extending maturities to 2030, which includes $1 billion of term loans outstanding [36][37] Q&A Session Summary Question: Update on generative AI consumer uptake and monetization - Management noted that AI service uptake is growing modestly, primarily among existing customers using technology to modify imagery [48][49] Question: Factors driving Q4 outperformance relative to guidance - The strong Q4 performance was attributed to a robust top line, improved gross margins, and recovery in production post-strikes [51][53] Question: Outlook for 2025 revenue growth by segment and data licensing revenue - Management does not provide specific segment guidance but expects continued stabilization in Agency and growth in Corporate [60][62]

Financial Data and Key Metrics Changes - Total operating expenses for full year 2024 were $66.6 million, down 17% year-over-year [24] - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023 [24] - GAAP net loss for full year was $63.2 million, equating to a net loss of $10.74 per share, compared to a GAAP net loss of $71.1 million or $14.60 per share for the full year 2023 [25] Business Line Data and Key Metrics Changes - General and administrative expenses totaled $21.9 million in the full year 2024, down from $26.9 million in 2023 [24] - Sales and marketing expenses were $4.5 million compared to $6.2 million in the prior year [24] Market Data and Key Metrics Changes - The company has expanded its partnerships with leading U.S. hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health [13][15] - The company is preparing for its first clinical use of the Version 1.0% system, which is expected to treat patients later in the year [21] Company Strategy and Development Direction - The company aims to transition into a clinical stage company in 2025, with a focus on robotic surgery innovations [8] - The Version 1.0% system is designed to deliver differentiated value to patients, surgeons, and hospitals, with a focus on minimally invasive outcomes [10][12] - The company is building a robust supply chain and manufacturing foundation to support its clinical trials and future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the successful completion of the Version 1.0% system integration and the potential impact on surgical procedures [9][28] - The company anticipates treating its first clinical patients by year-end 2025, with a de novo submission expected to be late in 2026 [21][26] Other Important Information - The company has faced some procurement challenges with key suppliers, but has managed to mitigate the impact on its timelines [20][36] - A new CFO, Sarah Romano, will join the company on April 1, bringing extensive financial leadership experience [22][23] Q&A Session Summary Question: Can you provide details on the supplier dynamic and its impact on clinical trial manufacturing? - Management acknowledged material procurement challenges with key suppliers that led to delays in component deliverables, but noted that they have resumed production [35][37] Question: When do you anticipate the clinical trial beginning? - Management indicated that the first patients will be treated later in the year, with plans to kick off pivotal trials shortly after [41][42] Question: Can you provide timing around the dossier submission? - The dossier submission is expected around the middle of the year, with the first patient timing dependent on approval [51] Question: What were the results of the cadaver lab tests? - The cadaver labs successfully performed ventral hernia repairs, and management expressed confidence in the system's performance [61] Question: Any updates on clinical trial design and patient expectations? - Management confirmed that trial design will be finalized after the first patients, allowing for flexibility in protocol adjustments [64]

Financial Data and Key Metrics Changes - The company reported fourth-quarter revenue of $1.84 billion, an increase of 6% year-over-year, driven mainly by new program wins and on-contract growth [18] - Full-year fiscal year 2025 revenue reached $7.48 billion, representing 3.1% organic growth, which is at the high end of the guidance provided at the start of the year [19] - Fourth-quarter adjusted EBITDA was $177 million, resulting in a margin of 9.6%, while full-year adjusted EBITDA was $710 million with a margin of 9.5% [19][20] - Adjusted diluted earnings per share for the fourth quarter was $2.57 and $9.13 for the full year, benefiting from strong operating performance and a lower effective tax rate [19] Business Line Data and Key Metrics Changes - Revenue from the commercial operating sector increased from less than $1 million in fiscal year 2022 to approximately $45 million in fiscal year 2025, with a goal of reaching approximately $100 million by fiscal year 2028 [12] - The company delivered net bookings of $1.3 billion in the fourth quarter and $6.6 billion for fiscal year 2025, resulting in a book-to-bill ratio of 0.9% [15] Market Data and Key Metrics Changes - The company submitted bids totaling $28 billion in fiscal year 2025, exceeding the initial plan of $22 billion, with a backlog of submitted bids increasing to just over $20 billion at year-end [16] - The company expects to drive its book-to-bill ratio to the target of 1.2% by the first half of FY 2026, contingent on ongoing uncertainties facing customers [17] Company Strategy and Development Direction - The company is focusing on transitioning from cost-plus contracts to fixed-price contracts, which is expected to improve margins while maintaining revenue levels [46][50] - The strategy emphasizes mission-critical programs and the infusion of cutting-edge technology, aligning with government efficiency initiatives [9][56] - The company is assessing its cost-plus portfolio to determine how much work could transition to fixed-type contracting over time [14] Management's Comments on Operating Environment and Future Outlook - Management noted that the financial impact from recent executive orders and program cancellations has been nominal, but they remain prepared for potential changes in the operating environment [8] - The company anticipates a headwind of approximately $200 million related to low-margin Air Force CloudOne compute and store revenue, which they chose to no-bid [24] - Management expressed confidence in achieving free cash flow targets of $11 per share in fiscal year 2026 and $12 in fiscal year 2027 [20][26] Other Important Information - The company plans to repurchase between $350 million to $400 million in FY 2026 and 2027 while maintaining capacity for capability-focused M&A or additional share repurchases [26] - Several members of the executive leadership team have indicated an intent to make discretionary purchases of company shares to align interests with shareholders [28] Q&A Session Summary Question: Impact of the $1.8 billion recompete on future book-to-bill - Management indicated that the win would bring them close to a trailing twelve-month book-to-bill ratio of 1.0% [32] Question: Details on the incremental $6 billion in submitted bids - The increase is attributed to a combination of standardized business development functions and a balanced pipeline of new business and recompete opportunities [35] Question: Nature of budget dollars in the bid pipeline - Management believes the current pipeline is competitive and can be funded, with a focus on mission-critical areas [41] Question: Transition from cost-plus to firm fixed price contracts - Management sees potential for higher margins with fixed-price contracts but does not expect a significant revenue decline [48] Question: Risks and opportunities related to DOD budget cuts - Management emphasized the importance of focusing on mission-critical programs to mitigate risks associated with budget reallocations [56] Question: Impact of federal workforce layoffs on business - Management has not seen significant impacts but is prepared to support customers as personnel changes occur [66] Question: Backlog and organic growth expectations - A high percentage of the expected organic growth is already in backlog, with a focus on contract growth rather than relying heavily on new business [75] Question: Confidence in guidance despite uncertainty - Management expressed confidence based on past performance and ongoing efforts to drive organic growth [90] Question: Strategy regarding civil versus defense work - The company has not shifted its strategy and continues to focus on mission-critical areas in both civil and defense sectors [104]

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Brandon Carney - B. Riley Young Li - Jefferies Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to t ...

Quanterix Corporation (NASDAQ:QTRX) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Joshua Young - Head of IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Sung Ji Nam - Scotiabank Operator Thank you for standing by. My name is Kathleen and I will be your conference operator today. At this time, I would like to welcome everyone to the ...